Infliximab-Related Infusion Reactions: Systematic Review
暂无分享,去创建一个
B. Weiss | I. Dotan | L. Lichtenstein | E. Israeli | S. Ben-Horin | S. Kivity | Iris Dotan | Y. Ron | Y. Chowers | Shomron Ben-Horin | Eran Israeli | Shmuel Kivity | Yehuda Chowers | Lev Lichtenstein | Yulia Ron | Gerald M. Fraser | Ronit Confino-Cohen | Batia Weiss | G. Fraser | R. Confino‐Cohen
[1] P. Saxena,et al. Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases , 2014, Expert opinion on biological therapy.
[2] M. Peppercorn,et al. Safety of infliximab in Crohn's disease: A large single‐center experience , 2010, Inflammatory bowel diseases.
[3] W. Crandall,et al. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model , 2003, Alimentary pharmacology & therapeutics.
[4] Ji Won Kim,et al. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study , 2013, Journal of gastroenterology and hepatology.
[5] R. Gordon. An operational classification of disease prevention. , 1983, Public health reports.
[6] W. Busse,et al. Middleton's Allergy: Principles and Practice , 2013 .
[7] M. Fraga,et al. Genome-wide profiling of bone reveals differentially methylated regions in osteoporosis and osteoarthritis. , 2013, Arthritis and rheumatism.
[8] L. Mayer,et al. Monoclonal antibodies, immunogenicity, and associated infusion reactions. , 2005, The Mount Sinai journal of medicine, New York.
[9] S. Kugathasan,et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction , 2002, American Journal of Gastroenterology.
[10] P. Rutgeerts,et al. Tolerability of Shortened Infliximab Infusion Times in Patients With Inflammatory Bowel Diseases: A Single-Center Cohort Study , 2011, The American Journal of Gastroenterology.
[11] S. Kugathasan,et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. , 2001, Inflammatory bowel diseases.
[12] P. Vereerstraeten,et al. RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN‐2, AND GAMMA‐INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS , 1989, Transplantation.
[13] Hae‐Sim Park,et al. Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[14] B. Göke,et al. Safety Aspects of Infliximab in Inflammatory Bowel Disease Patients , 2004, Digestion.
[15] U. Kopylov,et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[16] A. Matucci,et al. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction , 2012, Internal and Emergency Medicine.
[17] E. Keystone,et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. , 2004, The Journal of rheumatology.
[18] J. Salmon,et al. FcgammaRIIa is a target for modulation by TNFalpha in human neutrophils. , 2005, Clinical Immunology.
[19] E. Berardesca,et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis , 2005, The British journal of dermatology.
[20] A. Sheikh,et al. World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis , 2011, The World Allergy Organization journal.
[21] Z. Tulassay,et al. Repeated infliximab therapy after serum sickness-like reaction in Crohn's disease. , 2007, Journal of Emergency Medicine.
[22] A. Matucci,et al. Acute infusion reactions induced by monoclonal antibody therapy , 2011, Expert review of clinical immunology.
[23] Y. Liu,et al. Characteristics of anaphylaxis‐inducing IgG immune complexes triggering murine passive systemic anaphylaxis , 2013, Allergy.
[24] M. Bala,et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[25] R. Cohen,et al. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. , 2004, Drugs.
[26] V. Diehl,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .
[27] P. Brennan,et al. Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to mAbs : 105 desensitizations in 23 patients , from evaluation to treatment , 2011 .
[28] A. Matucci,et al. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management , 2011, Current opinion in allergy and clinical immunology.
[29] S. Hanauer,et al. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians , 2002, American Journal of Gastroenterology.
[30] A. Cheifetz,et al. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). , 2014, Gastroenterology clinics of North America.
[31] M. B. Moss,et al. Reações infusionais imediatas a agentes imunobiológicos endovenosos no tratamento de doenças autoimunes: experiência de 2.126 procedimentos em um centro de infusão não oncológico , 2014 .
[32] C. Lees,et al. The safety profile of anti‐tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient‐years follow‐up , 2009, Alimentary pharmacology & therapeutics.
[33] F. Aubin,et al. The complexity of adverse side-effects to biological agents. , 2013, Journal of Crohn's & colitis.
[34] H. Tilg,et al. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. , 2010, Journal of Crohn's & colitis.
[35] J. Dwyer,et al. Desensitization to vancomycin. , 1984, Annals of internal medicine.
[36] K. Bendtzen,et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.
[37] A. Zinsmeister,et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.
[38] Yoshiya Tanaka,et al. Efficacy and safety of reducing duration of infliximab infusion , 2014, Modern rheumatology.
[39] John A. Godfrey,et al. Delayed Hypersensitivity Reaction and Acute Respiratory Distress Syndrome Following Infliximab Infusion , 2002, Inflammatory bowel diseases.
[40] J. Betteridge,et al. Delayed hypersensitivity reaction with infliximab: unusual to occur after initial dose. , 2012, Inflammatory bowel diseases.
[41] A. Matucci,et al. Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions , 2010, Allergy.
[42] P. Rutgeerts,et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.
[43] S. Clark,et al. Variation in Infliximab Administration Practices in the Treatment of Pediatric Inflammatory Bowel Disease , 2013, Journal of pediatric gastroenterology and nutrition.
[44] B. Wallaert,et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions , 2006, Alimentary pharmacology & therapeutics.
[45] M. V. van Oijen,et al. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. , 2008, Drug safety.
[46] F. Nagy,et al. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study , 2009, BMC gastroenterology.
[47] A. Cheifetz,et al. The impact of infliximab infusion reactions on long‐term outcomes in patients with Crohn’s disease , 2008, Alimentary pharmacology & therapeutics.
[48] M. Julsgaard,et al. Serum sickness-like reaction due to Infliximab reintroduction during pregnancy. , 2013, Journal of Crohn's & colitis.
[49] J. Adler,et al. Meta‐analysis: rapid infliximab infusions are safe , 2013, Alimentary pharmacology & therapeutics.
[50] R. Baldassano,et al. Human Antichimeric Antibody in Children and Young Adults with Inflammatory Bowel Disease Receiving Infliximab , 2004, Journal of pediatric gastroenterology and nutrition.
[51] G. Schuler,et al. Infliximab in the treatment of moderate to severe atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.
[52] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[53] A. Sheikh,et al. World Allergy Organization anaphylaxis guidelines: summary. , 2011, The Journal of allergy and clinical immunology.
[54] L. Aarden,et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis , 2006, Annals of the rheumatic diseases.
[55] P. Bruhns,et al. The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. , 2013, Blood.
[56] P. Rutgeerts,et al. Serum sickness, encephalitis and other complications of anti-cytokine therapy. , 2009, Best practice & research. Clinical gastroenterology.
[57] S. Vermeire,et al. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay , 2011, Alimentary pharmacology & therapeutics.
[58] M. Peppercorn,et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.
[59] Paul Rutgeerts,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.
[60] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[61] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[62] C. Steenholdt. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease. , 2013, Danish medical journal.
[63] M. Milla,et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[64] W. Sandborn,et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials , 2009, Alimentary pharmacology & therapeutics.
[65] F. Finkelman,et al. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis , 2011, Proceedings of the National Academy of Sciences.
[66] M. Kris,et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] P. Baiardi,et al. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. , 2009, Clinical and experimental rheumatology.
[68] J. Sanderson,et al. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis , 2012, European journal of gastroenterology & hepatology.
[69] C. O'Morain,et al. Safety of infliximab in 10 years of clinical practice , 2011, European journal of gastroenterology & hepatology.
[70] P. Rutgeerts,et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[71] A. Tonnel,et al. Accoutumance médicamenteuse à l'infliximab dans la maladie de Crohn , 2005 .
[72] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[73] Olivia Carter-Pokras,et al. Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists , 2007, Digestive Diseases and Sciences.
[74] P. Rutgeerts,et al. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. , 2010, Journal of Crohn's & colitis.
[75] A. Griffiths,et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.
[76] R. Baldassano,et al. Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium , 2005, Inflammatory bowel diseases.
[77] E. Cabré,et al. Infliximab Reintroduction is Not Associated to a Higher Rate of Immune-related Adverse Effects in Patients With Inflammatory Bowel Disease Initially Treated With a Three-infusion Induction Regimen , 2010, Journal of clinical gastroenterology.
[78] L. Mayer,et al. Infusion reactions and their management. , 2006, Gastroenterology clinics of North America.
[79] D. Hong,et al. Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children. , 2014, The journal of allergy and clinical immunology. In practice.
[80] Edgar Ramiterre,et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study , 2013, Annals of the rheumatic diseases.
[81] K. Aalto,et al. Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid. , 2012, Clinical and Experimental Rheumatology.
[82] S. Sutherland. Progress in the characterization of venoms and standardization of antivenoms. , 1981, WHO offset publication.
[83] L. Peyrin-Biroulet,et al. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study. , 2014, Journal of Crohn's & colitis.
[84] W. Sandborn,et al. Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.
[85] L. Maas,et al. Serum sickness-like reactions in patients receiving intravenous infliximab. , 2006, The Journal of emergency medicine.
[86] W. Pichler. Adverse side‐effects to biological agents , 2006, Allergy.
[87] A. Keshavarzian,et al. A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency. , 2007, Gastroenterology & hepatology.
[88] A. Moss,et al. Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis , 2014, Inflammatory bowel diseases.
[89] J. Salmon,et al. FcγRIIa is a target for modulation by TNFα in human neutrophils , 2005 .
[90] Yu Bai,et al. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn’s disease , 2011, European journal of gastroenterology & hepatology.
[91] A. Sheikh,et al. World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence Base , 2013, International Archives of Allergy and Immunology.
[92] Sergio Gutierrez-Ureña,et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study , 2013, Annals of the rheumatic diseases.
[93] B. Korelitz,et al. Red man syndrome and infliximab. , 2003, Journal of clinical gastroenterology.
[94] K. Kolho,et al. Prevention of acute adverse events related to infliximab infusions in pediatric patients , 2009, Arthritis care & research.
[95] E. Cabré,et al. Infliximab safety profile and long‐term applicability in inflammatory bowel disease: 9‐year experience in clinical practice , 2010, Alimentary pharmacology & therapeutics.
[96] I. Moss,et al. Immediate infusional reactions to intravenous immunobiological agents for the treatment of autoimmune diseases: experience of 2126 procedures in a non-oncologic infusion centre. , 2014, Revista brasileira de reumatologia.
[97] S. Plevy,et al. The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.
[98] B. Sands,et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[99] J. Sany,et al. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis , 2005, Annals of the rheumatic diseases.
[100] P. Deepak,et al. T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study , 2013, The American Journal of Gastroenterology.
[101] D. Brennan,et al. Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.